MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study - MaaT Pharma

Télécharger le poster

Previous Post13 novembre 2025 : MaaT Pharma lance une augmentation de capital d’un montant d’environ 9 millions d’euros
Next PostMaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club